Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 DiabetesGlobeNewsWire • 07/21/20
Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual ConferenceGlobeNewsWire • 07/20/20
Lexicon Pharmaceuticals Presents Clinical Data at 80th American Diabetes Association Scientific SessionsGlobeNewsWire • 06/13/20
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell LinesGlobeNewsWire • 05/13/20
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/27/20
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 04/27/20
LEXICON PHARMACEUTICALS TO HOST VIRTUAL ANNUAL MEETING OF STOCKHOLDERS ON APRIL 23, 2020GlobeNewsWire • 04/07/20
LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAMGlobeNewsWire • 03/19/20
LEXICON PHARMACEUTICALS ANNOUNCES ADDITIONAL DATA ON TELOTRISTAT ETHYL’S ANTIPROLIFERATIVE EFFECTS IN PATIENTS WITH CARCINOID SYNDROMEGlobeNewsWire • 03/13/20
Lexicon Pharmaceuticals, Inc. (LXRX) CEO Lonnel Coats on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/12/20
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/12/20
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid SyndromeGlobeNewsWire • 01/24/20
Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 DiabetesGlobeNewsWire • 12/20/19
Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract CancerGlobeNewsWire • 12/03/19
Why Roku, Ollie's Bargain Outlet Holdings, and Lexicon Pharmaceuticals Slumped TodayThe Motley Fool • 12/02/19